Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Alx Oncology Holdings Inc (ALXO)

Alx Oncology Holdings Inc (ALXO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 344,161
  • Shares Outstanding, K 40,681
  • Annual Sales, $ 0 K
  • Annual Income, $ -83,460 K
  • 60-Month Beta 2.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.00
Trade ALXO with:

Options Overview Details

View History
  • Implied Volatility 183.00% ( +4.77%)
  • Historical Volatility 93.55%
  • IV Percentile 99%
  • IV Rank 89.04%
  • IV High 196.58% on 05/18/22
  • IV Low 72.61% on 03/18/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 90
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 2,066
  • Open Int (30-Day) 2,350

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.66
  • Number of Estimates 4
  • High Estimate -0.61
  • Low Estimate -0.68
  • Prior Year -0.40
  • Growth Rate Est. (year over year) -65.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.59 +4.08%
on 05/25/22
15.21 -48.06%
on 04/26/22
-7.21 (-47.72%)
since 04/25/22
3-Month
7.59 +4.08%
on 05/25/22
20.40 -61.27%
on 03/18/22
-8.95 (-53.12%)
since 02/25/22
52-Week
7.59 +4.08%
on 05/25/22
81.19 -90.27%
on 09/17/21
-44.30 (-84.87%)
since 05/25/21

Most Recent Stories

More News
ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage...

ALXO : 7.90 (+1.94%)
ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage...

ALXO : 7.90 (+1.94%)
ALX Oncology's (ALXO) Evorpacept Gets Orphan Drug Tag for GC

The FDA bestows an Orphan Drug status to ALX Oncology's (ALXO) lead candidate, evorpacept, for treating gastric cancer and gastroesophageal junction cancer.

RHHBY : 42.9900 (-0.54%)
ALKS : 28.85 (+1.76%)
CARA : 8.10 (-2.06%)
ALXO : 7.90 (+1.94%)
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage...

ALXO : 7.90 (+1.94%)
Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer

Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to...

ONCY : 1.0500 (-2.78%)
ONC.TO : 1.37 (unch)
LPTX : 1.1900 (+6.25%)
GMDA : 2.14 (+1.42%)
ALXO : 7.90 (+1.94%)
MRK : 93.75 (-0.94%)
New Strong Sell Stocks for January 19th

ONEM, ALXO, and AVNS have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2022

AVNS : 27.67 (+1.02%)
ONEM : 8.30 (+1.22%)
ALXO : 7.90 (+1.94%)
ALX Oncology Holdings Becomes Oversold (ALXO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

ALXO : 7.90 (+1.94%)
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage...

ALXO : 7.90 (+1.94%)
ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome

-- Complete remissions with cytogenetic responses, hematologic improvement, and transfusion independence were observed in patients with previously...

ALXO : 7.90 (+1.94%)
ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage...

ALXO : 7.90 (+1.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

ALX Oncology Holdings Inc.is a clinical-stage immuno-oncology company. It focuses on developing therapies for patients fighting cancer. The company's product candidate consist ALX148, which is in clinical stage. ALX Oncology Holdings Inc.is based in Burlingame, California.

See More

Key Turning Points

3rd Resistance Point 8.61
2nd Resistance Point 8.35
1st Resistance Point 8.12
Last Price 7.90
1st Support Level 7.63
2nd Support Level 7.37
3rd Support Level 7.14

See More

52-Week High 81.19
Fibonacci 61.8% 53.07
Fibonacci 50% 44.39
Fibonacci 38.2% 35.71
Last Price 7.90
52-Week Low 7.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar